The New Drug Reimbursement Game

افزودن به بوکمارک اشتراک گذاری 0 دیدگاه کاربران 5 (0)

A Regulator S Guide to Playing and Winning

مشارکت: عنوان و توضیح کوتاه هر کتاب را ترجمه کنید این ترجمه بعد از تایید با نام شما در سایت نمایش داده خواهد شد.

ترجمه این کتاب مشاهده همه کتاب های ترجمه نشده

A Regulator S Guide to Playing and Winning

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population s future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure.

Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society s welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.

"

لغو

گزارش تخلف

مغایرت عنوان کتاب با توضیحات و تصویر جلد
عدم رعایت حقوق نشر طبق قوانین جمهوری اسلامی ایران
محتوای مستهجن
توهین به قومیتها و محتوای نژادپرستی
توهین به اقیلیتهای مذهبی
اهانت به مقامات سیاسی و مذهبی
اشاعه ی کودک آزاری
سایر موارد

بستن

فرمت کتاب

ebook

زبان

english

تاریخ انتشار

2014

نویسنده

Brita Pekarsky

ناشر

Adis

شابک

9783319089027

20,000 تومان

خرید کتاب مطالعه نمونه درخواست ترجمه کتاب

خرید کتاب The New Drug Reimbursement Game

The New Drug Reimbursement Game

گزارش تخلف

فرمت کتاب

ebook

زبان

english

تاریخ انتشار

2014

نویسنده

ناشر

شابک

کتاب های مرتبط

Early Hollywood

Cemeteries of Seattle

Seattle's Green Lake

U.S. Penitentiary Leavenworth

Aubuchon Hardware

9780738574509

Great Sand Dunes National Park

Hot Rodding in Ventura County

San Francisco's Twin Peaks

Paramedic Crash Course with Online Practice Test

Bob Miller's math for the new GRE

The essentials of United States history, 1500 to 1789, from colony to republic

Wheels of Life

Jude's Herbal Home Remedies

Your Neighborhood Gives Me the Creeps

Serpent of Wisdom

Heal Yourself with Angels

Llewellyn's Truth about Chakras

Spirit Boards for Beginners

The Ghost in the Coal Cellar

365 Ways to Attract Good Luck

دیدگاه کاربران